Payment overview · 2025
General Payments
$485.90
24 reported records · 14 companies
Healthcare provider profile · identity verified
Sarah Taylor, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · BELPRE, OH · NPI 1033372123
Verified facts
What the public records show
CMS Open Payments records show Sarah Taylor, D.O. received $485.90 in general payments during 2025 across 24 reported records.
Exact Sciences Corporation accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $105.28 | 21.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.60 | 10.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.06 | 9.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.34 | 7.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.45 | 7.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.28 | 7.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.93 | 6.2% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $28.12 | 5.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.83 | 5.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.11 | 4.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.25 | 3.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $18.13 | 3.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.60 | 3.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.92 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $485.90 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $105.28 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.60 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $49.60 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $45.06 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $38.34 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $38.34 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $38.34 | 2 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $37.45 | 2 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $37.45 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $28.12 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 82 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 38 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 20 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 240 | 66 |
| Gabapentin | Gabapentin | 217 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 212 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 185 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 46 |
| Lisinopril | Lisinopril | 154 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 142 | 34 |
| Omeprazole | Omeprazole | 139 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 30 |
| Losartan Potassium | Losartan Potassium | 123 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 18 |
| Metformin Hcl | Metformin Hcl | 92 | 23 |
| Alprazolam | Alprazolam | 87 | 23 |
| Montelukast Sodium | Montelukast Sodium | 84 | 16 |
| Jardiance | Empagliflozin | 82 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 26 |
| Potassium Chloride | Potassium Chloride | 76 | 19 |
| Famotidine | Famotidine | 74 | 14 |
| Furosemide | Furosemide | 68 | 20 |
| Farxiga | Dapagliflozin Propanediol | 66 | 16 |
| Mirtazapine | Mirtazapine | 65 | 17 |
| Sertraline Hcl | Sertraline Hcl | 65 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 16 |
| Spironolactone | Spironolactone | 57 | 14 |
| Donepezil Hcl | Donepezil Hcl | 52 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 20 |
| Eliquis | Apixaban | 48 | suppressed |
| Meloxicam | Meloxicam | 48 | 15 |
| Simvastatin | Simvastatin | 48 | 14 |
| Trazodone Hcl | Trazodone Hcl | 48 | 14 |
| Ezetimibe | Ezetimibe | 44 | 11 |
| Rybelsus | Semaglutide | 44 | suppressed |
| Carvedilol | Carvedilol | 43 | 13 |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Celecoxib | Celecoxib | 40 | 12 |
| Allopurinol | Allopurinol | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 15 |
| Ozempic | Semaglutide | 38 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 13 |
| Topiramate | Topiramate | 37 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 33 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Prednisone | Prednisone | 18 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 11 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 16 |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $485.90 · 24 records | Exact Sciences Corporation | AREXVY, AVYCAZ, Auvelity, BEXSERO, CAPVAXIVE, Cologuard Collection Kit, DALVANCE, Dexcom G6 Transmitter, EVENITY, GARDASIL 9, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, ROTATEQ, SHINGRIX, SPRAVATO, TEFLARO, TZIELD, VAXELIS, VAXNEUVANCE, VYNDAMAX, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error